Under laboratory conditions the biomaterial induces the proteins and hormones needed for the initial inflammatory response. "We know that it does the right thing to the blood to begin bone regeneration," said Goss. The next step is to determine whether later stages in the bone regeneration process are happening. Successful preliminary results were presented at the Australia New Zealand Orthopaedic Research Society's meeting late last year, and animal trials are currently underway. If the trials are successful the biomaterial will move to human trials to treat patients with significant bone defects. According to the researchers bone disease affect more than a million people worldwide. They say half a million bone grafts are performed annually in the United States to fill fractures that cannot naturally heal. Related Links: |
advertisement
Put Discovery News on Your Site!
|
-
our sites
-
video
mobile
-
shop
-
stay connected
-
corporate
